dutilox 30 mg gél. gastro-résist.
towa pharmaceutical europe s.l. - chlorhydrate de duloxétine 33,678 mg - eq. duloxétine 30 mg - gélule gastro-résistante - 30 mg - chlorhydrate de duloxétine 33.678 mg - duloxetine
dutilox 60 mg gél. gastro-résist.
towa pharmaceutical europe s.l. - chlorhydrate de duloxétine 67,356 mg - eq. duloxétine 60 mg - gélule gastro-résistante - 60 mg - chlorhydrate de duloxétine 67.356 mg - duloxetine
dutilox 30 mg gél. gastro-résist.
towa pharmaceutical europe s.l. - chlorhydrate de duloxétine 33,678 mg - eq. duloxétine 30 mg - gélule gastro-résistante - duloxetine
dutilox 30 mg gél. gastro-résist.
towa pharmaceutical europe s.l. - chlorhydrate de duloxétine 33,678 mg - eq. duloxétine 30 mg - gélule gastro-résistante - duloxetine
dutilox 60 mg gél. gastro-résist.
towa pharmaceutical europe s.l. - chlorhydrate de duloxétine 67,356 mg - eq. duloxétine 60 mg - gélule gastro-résistante - duloxetine
dutilox 60 mg gél. gastro-résist.
towa pharmaceutical europe s.l. - chlorhydrate de duloxétine 67,356 mg - eq. duloxétine 60 mg - gélule gastro-résistante - duloxetine
co norfloxacin comprimé
cobalt pharmaceuticals company - norfloxacine - comprimé - 400mg - norfloxacine 400mg - quinolones
recofol edta 10mg/ml émulsion injectable/perfusion
primex pharmaceuticals ag - propofolum - Émulsion injectable/perfusion - propofolum 10 mg, phosphatidum ovi depuratum, dinatrii edetas, glycerolum, sojae oleum 100 mg, aqua ad iniectabile q.s. ad emulsionem pro 1 ml. - allgemeinnarkoticum - synthetika
sitagliptin sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabète sucré, type 2 - les médicaments utilisés dans le diabète - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.